IP Library Granted Patent US 11,667,671
Granted Patent B2
US 11,667,671 · App. 16/911,511 · Granted Jun 6, 2023

Separation method

Inventors: Annika Forss (Uppsala, SE); Mats Ander (Uppsala, SE); Tomas Bjorkman (Uppsala, SE); Hans Blom (Uppsala, SE); Jesper Hansson (Uppsala, SE); Gustav Rodrigo (Uppsala, SE)
Assignee: Cytiva BioProcess R&D AB
C07K1/165B01D15/1807B01D15/1864B01D15/34B01J20/285B01J20/286C07K1/22C07K14/31C07K16/00C07K2317/21C07K2317/31C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,667,671
App. No.
16/911,511
Granted
Jun 6, 2023
Kind
B2
Abstract

The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.

Claims (21)

1. A method of isolating an immunoglobulin, comprising the steps of:

a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein said porous support comprises cross-linked polymer particles having a pore size corresponding to an inverse gel filtration chromatography Kd value of 0.69-0.85 for dextran of Mw 110 kDa;

b) contacting a liquid sample comprising an immunoglobulin with said separation matrix;

c) washing said separation matrix with a washing liquid;

d) eluting the immunoglobulin from the separation matrix with an elution liquid; and

e) cleaning the separation matrix with a cleaning liquid comprising more than 2M NaOH,

wherein in step e) the contact time between the separation matrix and the cleaning liquid is 3 minutes or less.

2. The method of claim 1 , wherein said separation matrix has a maximum pressure of at least 0.58 MPa when packed at 300+/−10 mm bed height in a chromatography column having a diameter of 35 mm.

3. The method of claim 1 , wherein said immunoglobulin comprises an Fc fusion protein.

4. The method of claim 1 , wherein said immunoglobulin has a hydrodynamic radius of at least 6.0 nm.

5. The method of claim 1 , wherein said immunoglobulin comprises a bispecific, trispecific or polyspecific antibody.

6. The method of claim 5 , wherein said method separates half antibodies or homodimeric antibodies from said bispecific, trispecific or polyspecific antibody.

7. The method of claim 1 , wherein said immunoglobulin comprises a conjugated antibody.

8. The method of claim 1 , wherein said immunoglobulin comprises an antibody fragment.

9. The method of claim 1 , wherein the separation matrix is a Protein A chromatography column.

10. The method of claim 1 , wherein steps b)-e) are repeated at least 10 times.

11. The method of claim 1 , wherein in step b) the pH is 6-8.

12. The method of claim 1 , wherein in step b) the residence time of said liquid sample on said separation matrix is 2-20 min.

13. The method of claim 1 , which is performed in a continuous or semicontinuous multicolumn chromatography process.

14. The method of claim 1 , which is performed in a periodic countercurrent chromatography (PCC) process.

15. The method of claim 1 , wherein the separation matrix is an antibody affinity chromatography cross-linked agarose matrix having alkaline-stabilized protein A-derived ligands.

Assignments (2)
CHANGE OF NAME Recorded May 11, 2021
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 056199/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2020
From: FORSS, ANNIKA; ANDER, MATS; BJORKMAN, TOMAS; BLOM, HANS; HANSSON, JESPER; RODRIGO, GUSTAV
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 053035/0603 →
Priority Claims (1)
GB 1608229 · May 11, 2016 · national
Continuity (4)
Continuation 15798784 · Oct 31, 2017
Continuation In Part 15348699 · Nov 10, 2016
Continuation In Part 15282367 · Sep 30, 2016
Related Publication 20200317725A1 · Oct 8, 2020
Cited By (1)
US 12,448,411